The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.r Pericarditis (see also under XIIc)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.h Nontuberculous pulmonary mycobacterial infection/superinfection

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.av The chemotherapy lung

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.f ARDS and the hemolytic-uremic syndrome (HUS)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.ac Pneumothorax, bilateral

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVII. Mediastinal involvement

XLVII.h Pneumomediastinum

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.f Hiccup

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.o Pneumorachis

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

L. Miscellaneous

L.t Cavitation/necrosis of lung tumor or metastases

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.m Atrial fibrillation

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

LV. Imaging

LV.bh Imaging: Tumoral cavitation

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LV. Imaging

LV.by Imaging: Air or an air crescent around lung tumor or metastase(s)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.g BAL: Atypical epithelial cells (at times poetically named

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LVIII. Pathology

LVIII.ba Path: Thrombosis in pulmonary arterioles/venules

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.bx Path: Granulomatous lymphadenopathy

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

LIX. Infections & related conditions

LIX.r Fungal infection (pulmonary/extrapulmonary)

LIX. Infections & related conditions

LIX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

LX. Neoplastic conditions

LX.d Malignant mesothelioma (pleural, pericardial)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.b Pneumorenal syndrome (w/wo ANCAs)

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.k Tracheal narrowing - Sabre sheath trachea

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLVI. Pulmonary vasculopathy

XLVI.e Fat/oil embolism - The FES embolism syndrome

XLVI. Pulmonary vasculopathy

XLVI.ac Right ventricular outflow tract compression

XLVII. Mediastinal involvement

XLVII.c Mediastinal lipomatosis

XLVII. Mediastinal involvement

XLVII.g Hemomediastinum - Mediastinal hematoma

XLVII. Mediastinal involvement

XLVII.h Pneumomediastinum

XLVII. Mediastinal involvement

XLVII.j Compression of mediastinal structures/organs

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.f Hiccup

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.m Epidural thoracic lipomatosis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.p Disordered breathing during sleep - Sleep apnea

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.v Generalized myopathy/muscle weakness

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.au Scleroderma renal crisis

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.bb Rhabdomyolysis (see also under Xj)

L. Miscellaneous

L.s Rib fracture

L. Miscellaneous

L.ad Vertebral compression fracture

L. Miscellaneous

L.af Cushing syndrome

L. Miscellaneous

L.aq Diminished efficacy of antineoplastic immunotherapy

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.x Hypertrophic cardiomyopathy

LV. Imaging

LV.av Imaging: Subpleural fat deposits

LV. Imaging

LV.aw Imaging: Mediastinal fatty deposits

LIX. Infections & related conditions

LIX.a Respiratory tract infection incl. pneumonia

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.d Pneumocystis jiroveci pulmonary colonization

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

LIX. Infections & related conditions

LIX.m Fungal airway infection

LIX. Infections & related conditions

LIX.o Nocardia pulmonary/systemic infection

LIX. Infections & related conditions

LIX.r Fungal infection (pulmonary/extrapulmonary)

LIX. Infections & related conditions

LIX.u Strongyloides stercoralis hyperinfection (w/wo DAH)

LIX. Infections & related conditions

LIX.v Hypogammaglobulinemia - Antibody deficiency

LIX. Infections & related conditions

LIX.ah A falsely negative/indeterminate IGRA test result

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.m Coagulopathy

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.d Exacerbation or deterioration of preexisting COPD

XLIII. Airway involvement

XLIII.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.af Sputum production - Bonchorrhea - ‘Bronchitis’

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.i Pleuritis (can cause chest pain)

XLV. Pleural and/or pericardial involvement

XLV.t Serositis - Polyserositis

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.r Myasthenia gravis - Myasthenic-like syndrome

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.a DRES syndrome - DRESS-like reaction

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.w Multiple organ dysfunction/failure (MODS/MOF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ao Immune-related adverse effect/toxicity

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ax Connective tissue disease

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.az Polymyalgia rheumatica

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.bj Temporal arteritis (Horton’s)

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

L. Miscellaneous

L.v Adrenal suppression

L. Miscellaneous

L.ad Vertebral compression fracture

L. Miscellaneous

L.ar Graft vs. host disease in transplant recipients

L. Miscellaneous

L.as Deterioration of graft function in SOT recipients

L. Miscellaneous

L.av Nonrespiratory AE of interest

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.s Heart failure (biventricular, congestive)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LI. Cardiovascular involvement / toxicity

LI.az Necrotizing myocarditis (w/o evidence for CAD)

LI. Cardiovascular involvement / toxicity

LI.bd Sudden cardiac death

LV. Imaging

LV.k Imaging: An area or areas of consolidation

LV. Imaging

LV.v Imaging: Centrilobular micronodules (can be diffuse)

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LV. Imaging

LV.bj Imaging: Avid pleural uptake on PET-scan

LV. Imaging

LV.bk Imaging: F18-PET scan positive lympadenopathy

LV. Imaging

LV.bv Imaging: A subsolid lung nodule or nodules

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.f Path: ILD with a granulomatous component (see also Im)

LVIII. Pathology

LVIII.j Path: Micronodular organizing pneumonia/BOOP

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LVIII. Pathology

LVIII.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

LVIII. Pathology

LVIII.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

LVIII. Pathology

LVIII.bx Path: Granulomatous lymphadenopathy

LVIII. Pathology

LVIII.co Path: Myocarditis

LVIII. Pathology

LVIII.cr Path: Myocardial vasculitis

LVIII. Pathology

LVIII.cv Path: Pneumocyte vacuolization

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.q Viral pneumonia

LIX. Infections & related conditions

LIX.r Fungal infection (pulmonary/extrapulmonary)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.g Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.j Anti-GBM-related pneumorenal syndrome and DAH (Goodpasture) or flare of

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.m Coagulopathy

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.d Exacerbation or deterioration of preexisting COPD

XLIII. Airway involvement

XLIII.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

XLIII. Airway involvement

XLIII.w Bronchiolitis (a clinical-imaging pattern suggestive of)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.af Sputum production - Bonchorrhea - ‘Bronchitis’

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.au Rhinosinusitis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.h Dyspnea, unexplained otherwise

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.r Myasthenia gravis - Myasthenic-like syndrome

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.y A flare or relapse of preexisting myasthenia gravis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.a DRES syndrome - DRESS-like reaction

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.w Multiple organ dysfunction/failure (MODS/MOF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.az Polymyalgia rheumatica

L. Miscellaneous

L.as Deterioration of graft function in SOT recipients

L. Miscellaneous

L.bi Esophageal necrosis

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LI. Cardiovascular involvement / toxicity

LI.az Necrotizing myocarditis (w/o evidence for CAD)

LII. Esophageal involvement

LII.c Esophageal stenosis/stricture

LII. Esophageal involvement

LII.d Esophageal toxicity

LV. Imaging

LV.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

LV. Imaging

LV.v Imaging: Centrilobular micronodules (can be diffuse)

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

LV. Imaging

LV.ak Imaging: A 'tree-in-bud' pattern

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.r Path: Alveolar hemorrhage (see also IIIa)

LVIII. Pathology

LVIII.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

LVIII. Pathology

LVIII.am Path: Peribronchiolar granulomas

LVIII. Pathology

LVIII.au Path: Airway inflammation

LIX. Infections & related conditions

LIX.a Respiratory tract infection incl. pneumonia

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.ai Bordetella bronchiseptica pulmonary infection